Cover Image


View/Hide Left Panel

•   By 2019: Import substitution for 140 drugs and vaccines.

•   By 2020: Domestic innovations for 20 exports.

Achieving domestic innovations for export (2016–2020):

•   Financing: Grants, venture financing, industry financing. Initial state investment of $1 billion, and eventually industry investment of $1 billion.

•   Drugs based on postgenomic period achievements.

•   Research centers for drug design.

•   New generation of research specialists, together with consultations with foreign scientists.


A. Regional Biotechnology Programs: Tatarstan Republic, Chuvash Republic, Kirov Oblast, Penza Oblast, Karelia Republic, Tomsk Oblast, Novosibirsk Oblast, Kaliningrad Oblast, Belgorod Oblast, Voronezh Oblast.

B. Enhancement of Business Structures: Microgen production of vaccines. Rosagrobioprom production of animal drugs. Bioprocess Group production of genetically engineered products. Biotechnology Corporation development of biofuels. Biochem Zavod development and production of animal feed proteins and biofuels.

C. Other Initiatives:

•   State program of “Biotechnology Development” (BIO 2020).

•   Technology platforms: “Medicine of the Future,” “Bioindustry and Bioresources,” “Bioenergy.”

•   Ten new investment projects.

•   Skolkovo and Rusnano megaprojects.

•   New venture funds.

•   Target program of Russian Academy of Sciences, “Fundamental Science for Medicine.”

•   Increased funding for Federal Target Programs and for Russian Fund for Basic Research.

•   Outreach through new journals, Web sites, and conferences.

•   Increased educational opportunities for young scientists.

SOURCE: Representatives of Russian Biotechnology Society and Bioindustry Association, September 2011.

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement